BioTrinity 2014 can count over 120 investment delegates thus far confirmed from 95 firms, significantly up again on the previous year. We are delighted that corporate venture fund involvement at BioTrinity has continued to grow!  The new trend continues: a number of investor firms are sending more than one delegate, increasing the chance of you getting that all important meeting.  This year again, we actively monitor the quality of investment firms which we allow to participate, which we continue to improve year-on-year.  The vast majority of those listed below are already registered, with the remainder having confirmed they will attend.  This page is updated weekly or more frequently, so come back regularly to see which new investors sign up to attend.

Investment Firms participating in 2014:

  • AbbVie, Inc (USA)
  • Abingworth (UK)
  • Advent Venture Partners (UK)
  • Akesios Associates (UK)
  • Albion Ventures LLP (UK)
  • Andy Richards (UK)
  • Apposite Capital (UK)
  • Arthurian Life Sciences (UK)
  • Auriga Partners (France)
  • Bay City Capital (US)
  • Beringea LLP (UK)
  • Bluelane Capital (USA)
  • Boehringer Ingelheim Venture Fund GmbH (Germany)
  • Cambridge Angels - Various (UK)
  • Cambridge Innovation Capital plc (UK)
  • Delta Partners (Ireland)
  • DFJ Esprit (UK)
  • ECI Partners (UK)
  • Edmond de Rothschild Investment Partners (France)
  • Entrepreneurs Fund (UK)
  • Epidarex Capital (UK)
  • Esperante (Netherlands)
  • Fidelity Biosciences (UK)
  • Finance Wales (UK)
  • Forbion Capital Partners (Netherlands)
  • Fountain Healthcare Partners (Ireland)
  • GHO Capital (UK)
  • Gilde Healthcare Partners (Netherlands)
  • HNW Family Fund (UK)
  • Imperial Innovations (UK)
  • Index Ventures (UK)
  • Inventages Venture Capital (UK)
  • Invesco Perpetual (UK)
  • IP Group plc (UK)
  • IPF Partners (Luxembourg)
  • J&J Dev Corp (USA)
  • Kreos Capital (UK)
  • London Business Angels - Various (UK)
  • Longwall Ventures (UK)
  • LSP Health Economics Fund (Belgium)
  • Lundbeckfond Ventures (Denmark)
  • Mann BioInvest (UK)
  • MedImmune Ventures (USA)
  • Mercia Fund Management (UK)
  • Mérieux Developpement (France)
  • MRL Venture Fund (USA)
  • Midven (UK)
  • Mitsui & Co Global Investment (USA)
  • MP Healthcare Venture Management (USA)
  • MS Ventures (Switzerland)
  • MVM Life Science Partners (UK)
  • NBGI Ventures (UK)
  • NeoMed (Switzerland)
  • NetScientific plc (UK)
  • New Enterprise Associates (USA)
  • New Hill Management (UK)
  • Norgine Ventures Investment (UK)
  • Novartis Venture Funds (Switzerland)
  • Novo A/S (Denmark)
  • Novo Nordisk (Denmark)
  • Novo Seeds (Denmark)
  • O2H Ventures (UK)
  • Oriel Securities (UK)
  • Oxford Capital (UK)
  • Oxford Finance (USA)
  • Oxford Spin-out Equity Management (UK)
  • Oxford Technology (UK)
  • Peel Hunt (UK)
  • Phase4 Partners (UK)
  • Rosetta Capital (UK)
  • Royal Society Enterprise Fund (UK)
  • SEP (UK)
  • Seroba Kernel (Ireland)
  • Seventure Partners (France)
  • Silicon Valley Bank (UK)
  • Sixth Element Capital (UK)
  • Sofinnova Partners (France)
  • Sofinnova Ventures (Ireland)
  • SPARK Impact (UK)
  • SR One (UK)
  • SV Life Sciences (UK)
  • Syncona Partners (UK)
  • Synergis Technologies (UK)
  • Takeda Ventures (USA)
  • Technology Strategy Board (UK)
  • The Summit Group (UK)
  • TVM Capital (Germany)
  • Unilever Ventures (UK)
  • venBIO LLC (USA)
  • Ventac Partners (Spain)
  • Visium Asset Management (UK)
  • Wellcome Trust (UK)
  • Wellington Parnters (Germany)
  • Wombat Capital (USA)
  • Wren Capital (UK)
  • Yorkville Advisors (USA)
  • Ysios Capital (Spain)
  • Zoetis (US)

See the list of previous years' investors

BioTrinity 2013 highlights
877 delegates from 28 countries
520 companies
168 speakers
86 company presentations
1679 scheduled one-to-one meetings
97 investors from 11 countries
66 exhibitors
32 global pharma/corporate venture